New CLASSIC technique uses AI and massive DNA libraries to predict genetic circuit performance faster and more accurately.
Genetic disorders occur due to alterations in the primary genetic material, deoxyribonucleic acid (DNA), of an organism.
CLASSIC enables large-scale testing of complex DNA circuits in human cells, advancing data-driven synthetic biology.
The goals of this project represent the culmination of more than two decades of 3D bioprinting innovation by Chen and his lab ...
Benefits seen from embracing platform technologies, combined with the role such systems played during the pandemic, are key dynamics.
Zacks Small Cap Research on MSN
YDES: YD Biopharma is an integrated biotechnology company that is poised to have a transformational year as it expands business operations
YDES YD Bio (NASDAQ:YDES) is an integrated biotechnology company that combines diagnostics, precision medicine, and ...
The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...
The companies Kymera Therapeutics, Immunovant, and Dyne Therapeutics bagged the biggest biotech funding rounds overall in ...
A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an ...
Understand the role of reproductive biotech in overcoming biological limits in fertility treatments and enhancing success ...
Avista Therapeutics, a preclinical gene therapy company built on deep clinical, computational and gene therapy expertise, today announced the significant expansion of its gene therapy platform.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback